文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

口服奥福格列酮联合滴定甘精胰岛素治疗2型糖尿病:ACHIEVE-5随机临床试验

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

ACHIEVE-5为随机双盲3期研究,在546例甘精胰岛素控制不佳的2型糖尿病患者中比较口服奥福格列酮3、12、36 mg与安慰剂。第40周时各剂量组HbA1c降幅均显著优于安慰剂,体重下降更明显,且未增加临床显著低血糖风险。

要点

  • 奥福格列酮3、12、36 mg组HbA1c较基线分别下降1.58%、1.88%、1.82%,安慰剂组下降0.79%。
  • 各剂量组体重降幅分别为2.6%、4.8%、5.4%,安慰剂组为0.2%。
  • 最常见不良事件为轻度至中度胃肠道反应,未增加临床显著低血糖风险。

核心结论

  • 在甘精胰岛素控制不佳的2型糖尿病患者中,加用口服奥福格列酮可显著改善血糖控制和体重,且不增加低血糖风险。

研究设计与样本

  • 随机、双盲、3期研究,在美国、巴西、中国、日本和罗马尼亚72个中心开展,时间2023年11月10日至2025年9月15日。
  • 纳入546例使用甘精胰岛素(联合或不联合二甲双胍和/或SGLT2抑制剂)的2型糖尿病成人,按1:1:1:1随机分配至奥福格列酮3 mg(n=137)、12 mg(n=132)、36 mg(n=136)或安慰剂(n=141),疗程40周。

主要发现

  • 第40周HbA1c较基线平均变化:奥福格列酮3 mg组-1.58%、12 mg组-1.88%、36 mg组-1.82%,安慰剂组-0.79%。
  • 所有关键次要结局均显示奥福格列酮显著优于安慰剂。
  • 体重较基线平均百分比变化:3 mg组-2.6%、12 mg组-4.8%、36 mg组-5.4%,安慰剂组0.2%。

关键数值与推荐

  • 主要结局为12 mg和36 mg每日一次组第40周HbA1c较基线平均变化。
  • 关键次要结局包括3 mg组HbA1c变化、HbA1c<7.0%及≤6.5%达标比例、体重变化及百分比变化。
  • 奥福格列酮最常见不良事件为轻度至中度胃肠道反应。
  • 奥福格列酮未增加临床显著低血糖风险(与安慰剂相比)。

临床怎么用

  • 对于甘精胰岛素治疗血糖不达标的2型糖尿病患者,可考虑加用口服奥福格列酮以改善血糖并减轻体重。
  • 用药期间需关注胃肠道不良反应,但低血糖风险未见显著增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effects of orforglipron, an oral, nonpeptide glucagon-like peptide 1 receptor agonist, added to insulin glargine for treatment of type 2 diabetes have not been described. OBJECTIVE: To assess efficacy and safety of orforglipron added to titrated insulin glargine in adults with type 2 diabetes and inadequate glycemic control. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, phase 3 study conducted at 72 sites across the US, Brazil, China, Japan, and Romania between November 10, 2023, and September 15, 2025, in adults with type 2 diabetes taking insulin glargine with or without metformin and/or sodium-glucose cotransporter 2 inhibitors over 40 weeks. INTERVENTIONS: Participants were randomized (1:1:1:1) to receive once-daily 3-mg (n = 137), 12-mg (n = 132), or 36-mg (n = 136) dosages of orforglipron or placebo (n = 141), in addition to titrated insulin glargine. MAIN OUTCOMES AND MEASURES: The primary outcome was mean hemoglobin A1c (HbA1c) change from baseline to week 40 (for the 12-mg once daily and 36-mg once daily dosages of orforglipron). Key secondary outcomes were mean HbA1c change from baseline (for the 3-mg once daily dosage of orforglipron), proportion of participants achieving HbA1c targets of lower than 7.0% and 6.5% or lower, and mean body weight change and percentage change from baseline to week 40. RESULTS: Among 546 randomized participants (median age, 61.0 [IQR, 26-95] years; 52.9% male; median duration of type 2 diabetes, 14.6 [IQR, 0.1-40.7] years; mean HbA1c, 8.50% [SD, 0.95%]; mean body mass index, 30.8 [SD, 6.1]), 507 (92.9%) completed the trial. At week 40, the mean changes from baseline in HbA1c were -1.58%, -1.88%, and -1.82% with orforglipron, 3 mg, 12 mg, and 36 mg once daily, respectively, vs -0.79% with placebo. Each dosage of orforglipron was superior to placebo (estimated treatment differences: 3 mg once daily, -0.78% [95% CI, -1.02% to -0.55%]; 12 mg once daily, -1.08% [95% CI, -1.33% to -0.83%]; 36 mg once daily, -1.03% [95% CI, -1.28% to -0.77%]; P < .001 for all). All key secondary outcomes demonstrated statistically significant differences in favor of orforglipron compared with placebo. Mean percentage body weight change from baseline was -2.6%, -4.8%, and -5.4% with orforglipron, 3 mg once daily, 12 mg once daily, and 36 mg once daily, respectively, vs 0.2% with placebo. The most frequent adverse events with orforglipron were gastrointestinal (mild to moderate). Orforglipron did not increase the risk of clinically significant hypoglycemia vs placebo. CONCLUSIONS AND RELEVANCE: In participants with type 2 diabetes inadequately controlled by insulin glargine, addition of oral orforglipron significantly improved glycemic control and body weight, without increasing hypoglycemia risk, compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06109311.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Giorgino F, D'Souza S, Ludwig L, et al. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. JAMA. 2026. PMID: 42251769. doi:10.1001/jama.2026.9512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。